Histopathological changes in tumor budding between biopsy and resected specimens from patients treated with preoperative S-1 chemotherapy for oral cancer.
S-1
oral
squamous cell carcinoma
tumor budding
Journal
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
ISSN: 1600-0714
Titre abrégé: J Oral Pathol Med
Pays: Denmark
ID NLM: 8911934
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
19
03
2019
revised:
23
05
2019
accepted:
13
06
2019
pubmed:
17
7
2019
medline:
15
1
2020
entrez:
17
7
2019
Statut:
ppublish
Résumé
S-1 is an oral anticancer agent containing tegafur, a prodrug of 5-fluorouracil (5-FU). Preoperative S-1 chemotherapy is performed to prevent tumor proliferation before surgery in oral squamous cell carcinoma (OSCC). The aim of this study was to evaluate the effects of preoperative S-1 chemotherapy on tumor budding. We examined 248 cases of OSCC and evaluated the budding scores in biopsy and resected specimens by keratin immunohistochemistry. In S-1-untreated patients, the budding scores in resected specimens tended to show a mild increase. S-1 treatment had the effect of lowering the budding score, although some cases with dramatically increased budding scores in resected specimens were found in the early phase of administration. Relapse-free survival showed a significant difference (P < .01) according to the presence or absence of S-1 treatment among patients with high budding scores. The present findings indicate that S-1 administration may be more effective in patients with high budding scores than in those with lower budding scores.
Sections du résumé
BACKGROUND
BACKGROUND
S-1 is an oral anticancer agent containing tegafur, a prodrug of 5-fluorouracil (5-FU). Preoperative S-1 chemotherapy is performed to prevent tumor proliferation before surgery in oral squamous cell carcinoma (OSCC). The aim of this study was to evaluate the effects of preoperative S-1 chemotherapy on tumor budding.
METHODS
METHODS
We examined 248 cases of OSCC and evaluated the budding scores in biopsy and resected specimens by keratin immunohistochemistry.
RESULTS
RESULTS
In S-1-untreated patients, the budding scores in resected specimens tended to show a mild increase. S-1 treatment had the effect of lowering the budding score, although some cases with dramatically increased budding scores in resected specimens were found in the early phase of administration. Relapse-free survival showed a significant difference (P < .01) according to the presence or absence of S-1 treatment among patients with high budding scores.
CONCLUSIONS
CONCLUSIONS
The present findings indicate that S-1 administration may be more effective in patients with high budding scores than in those with lower budding scores.
Substances chimiques
Antimetabolites, Antineoplastic
0
Drug Combinations
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
880-887Informations de copyright
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548-557.
Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist. 2002;7:288-323.
Tsukuda M, Kida A, Fujii M, et al. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer. 2005;93:884-889.
Obara S, Yamamoto K, Hosogai N, Yoshimura Y. Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma. Oral Oncol. 2005;41:276-282.
Nomura T, Murakami R, Toya R, et al. Phase II study of preoperative concurrent chemoradiation therapy with S-1 in patients with T4 oral squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2010;76:1347-1352.
Harada K, Sato M, Ueyama Y, et al. Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs. 2008;19:85-90.
Ito Y, Nakanishi KY, Hirai T, Nakao A, Kato T. Characterization of a novel lymph node metastasis model from human colonic cancer and its preclinical use for comparison of anti-metastatic efficacy between oral S-1 and UFT/LV. Cancer Sci. 2010;101:1853-1860.
Prall F. Tumor budding in colorectal carcinoma. Histopathology. 2007;50:151-162.
Seki M, Sano T, Yokoo S, Oyama T. Histologic assessment of tumor budding in preoperative biopsies to predict nodal metastasis in squamous cell carcinoma of the tongue and floor of the mouth. Head Neck. 2016;38:E1582-E1590.
Xie N, Wang C, Liu X, et al. Tumor budding correlates with occult cervical lymph node metastasis and poor prognosis in clinical early-stage tongue squamous cell carcinoma. J Oral Pathol Med. 2015;44:266-272.
Wang C, Huang H, Huang Z, et al. Tumor budding correlates with poor prognosis and epithelial-mesenchymal transition in tongue squamous cell carcinoma. J Oral Pathol Med. 2011;40:545-551.
Almangush A, Bello IO, Keski-Säntti H, et al. Depth of invasion, tumor budding, and worst pattern of invasion: prognostic indicators in early-stage oral tongue cancer. Head Neck. 2014;36:811-818.
Almangush A, Coletta RD, Bello IO, et al. A simple novel prognostic model for early stage oral tongue cancer. Int J Oral Maxillofac Surg. 2015;44:143-150.
Hori Y, Kubota A, Yokose T, et al. Predictive significance of tumor depth and budding for late lymph node metastases in patients with clinical N0 early oral tongue carcinoma. Head Neck Pathol. 2017;11:477-486.
Seki M, Sano T, Yokoo S, Oyama T. Tumour budding evaluated in biopsy specimens is a useful predictor of prognosis in patients with cN0 early stage oral squamous cell carcinoma. Histopathology. 2017;70:869-879.
Marangon Junior H, Leão PLR, Melo VVM, et al. Cell proliferation is associated with intensity of tumor budding in oral squamous cell carcinoma. J Oral Pathol Med. 2018;47:128-135.
Marangon Junior H, Rocha VN, Leite CF, de Aguiar MC, Souza PE, Horta MC. Laminin-5 gamma 2 chain expression is associated with intensity of tumor budding and density of stromal myofibroblasts in oral squamous cell carcinoma. J Oral Pathol Med. 2014;43:199-204.
Boxberg M, Jesinghaus M, Dorfner C, et al. Tumour budding activity and cell nest size determine patient outcome in oral squamous cell carcinoma: proposal for an adjusted grading system. Histopathology. 2017;70:1125-1137.
Almangush A, Pirinen M, Heikkinen I, Mäkitie AA, Salo T, Leivo I. Tumour budding in oral squamous cell carcinoma: a meta-analysis. Br J Cancer. 2018;118:577-586.
Umeda M, Yokoo S, Take Y, Omori A, Nakanishi K, Shimada K. Lymph node metastasis in squamous cell carcinoma of the oral cavity: correlation between histologic features and the prevalence of metastasis. Head Neck. 1992;14:263-272.
Izumo T, Kirita T, Ariji E, et al. General rules for clinical and pathological studies on oral cancer: a synopsis. Jpn J Clin Oncol. 2012;42:1099-1109.
Sloan P, Gale N, Hunter K, et al. Malignant surface epithelial tumours. In: El-Naggar AK, Chan J, Grandis JR, Takata T, Slootweg PJ, eds. WHO Classification of Head and Neck Tumours, 4th edn. Lyon: World Health Organization; 2017:109-111.
Elseragy A, Salo T, Coletta RD, et al. A proposal to revise the histopathologic grading system of early oral tongue cancer incorporating tumor budding. Am J Surg Pathol. 2019;43:703-709.
Almangush A, Youssef O, Pirinen M, Sundström J, Leivo I, Mäkitie AA. Does evaluation of tumour budding in diagnostic biopsies have a clinical relevance? A systematic review. Histopathology. 2019;74:536-544.
Tatsumi S, Matsuoka H, Hashimoto Y, Hatta K, Maeda K, Kamoshida S. Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy. Int J Clin Exp Pathol. 2013;7:204-212.
Miyata H, Yoshioka A, Yamasaki M, et al. Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. Cancer. 2009;115:3324-3334.
Eguchi T, Kodera Y, Nakanishi H, et al. The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: an in vivo study. In Vivo. 2008;22:707-717.
Oki E, Murata A, Yoshida K, et al. A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). Ann Oncol. 2016;27:1266-1272.
Sato H, Hatori M, Kurihara Y, Shirota T, Shintani S. S-1 mediates the inhibition of lymph node metastasis in oral cancer cells. Oncol Rep. 2009;22:719-724.